A small, mid-stage trial of Sangamo BioSciences' muscle-strengthening therapy produced promising results for a third of the ALS patients enrolled, roughly doubling the historical rate of muscle improvement among untreated patients.
Sangamo (SGMO) Chief Executive Edward Lanphier told Reuters that he was unaware of the magnitude of the improvement in strength among patients in the trial, which will run into the second quarter of 2010. Lanphier was also reluctant to lay out a timeline for a...